Crizotinib (PF-02341066)

Licensed by Pfizer 製品コードS1068

Crizotinib (PF-02341066)化学構造

分子量(MW):450.34

Crizotinib (PF-02341066)は一種の有効なc-MetとALK阻害剤で、細胞試験でIC50値が11 nMと24 nMです。

サイズ 価格(税別)  
JPY 36520.00
JPY 18260.00
JPY 28220.00
JPY 94620.00

文献中の使用例(71)

カスタマーフィードバック(12)

  • (c) Western blot analyses of p-Akt (Ser473) and p-S6RP (Ser235 and Ser236) in two RCT-E565 transplanted tumors treated with vehicle or PF02341066. Samples were isolated 4 h after the last dose from mice treated with PF02341066 for 3 d. (d) Responses of RCT-E565 transplanted tumors in athymic mice to PF02341066 or vehicle. Data are means ±s.e.m. (each group, n = 6). *P < 0.005, **P < 0.001 (Student,s t test).

    Nat Med 2011 17, 1116-1120. Crizotinib (PF-02341066) purchased from Selleck.

    Ba/F3 cells grown in the presence of IL-3, or Ba/F3 cells expressing native EML4-ALK (clone #2, #10, #101, and #155) and EML4-ALK L1196M (clone #216, #302, #303, and #355), were treated with CH5424802 or PF-02341066 for 48 hr, and then the viable cells were measured by the Cell Titer-Glo Luminescent Cell Viability Assay. IC50 values were determined by plotting the drug concentration versus percentage of cell growth inhibition. Data are shown as mean ±SD (n = 3).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

  • Mice bearing Ba/F3-EML4-ALK (clone #10) and EML4-ALK L1196M (clone #303) were administered vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg) orally once daily for 8 days. Tumor volume for each dose group was measured. Data are shown as mean ± SD (n = 5). Parametric Dunnett’s test: ***p < 0.001; N.S., not significant, versus vehicle treatment at final day. For pharmacodynamic assay, mice bearing Ba/F3-EML4-ALK (clone #10) and -EML4-ALK L1196M (clone #303) were orally administered at single dose of vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg), and the tumors were collected and lysed at 4 hr post-dosing. STAT3 and phosphorylated STAT3 (Tyr 705) were detected by immunoblot analysis using antibodies against each of them (n = 2 per group).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

    (A) Immunoblots of MPM cells treated with the indicated concentrations of crizotinib alone for 24 h with HGF stimulation.

    Sci Rep, 2016, 6:32992. Crizotinib (PF-02341066) purchased from Selleck.

  • Viability of Ba/F3 cells stably expressing DCTN1-ALK or EML4-ALK cDNAs after treatment with crizotinib (C). Ba/F3 cells transduced with lentiviral cDNA or empty vector were subjected to the assay, and the number of cells was counted at 72 hours.

    Oncologist, 2017, 22(2):158-164. Crizotinib (PF-02341066) purchased from Selleck.

    Combination of EGCG with c-MET inhibitor has enhanced inhibitory effects on the growth of OS cells. MG-63 and U-2OS cells were treated with crizotinib (0.05 mM) and/or EGCG (0.08 g/L) for 48 h, and the effects on cell apoptosis (b) were determined using flow cytometry. *P<0.05 versus the control; #P<0.05 versus crizotinib-treated groups or EGCG-treated groups

    Tumour Biol, 2016, 37(4):4373-82. Crizotinib (PF-02341066) purchased from Selleck.

  • (A) VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis. (B) Dose-response curves for both U0126 and axitinib control modulators of EMT. RLU, relative luminescence units.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

    Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

  • Crizotinib impaired tumor vascularization. a-e Representative photomicrographs (40×) of CD31 staining in negative control and indicated LFD, HFD, vehicle (veh) and crizotinib (criz) treated groups. b CD31 was quantified on 5–6 randomly selected regions of n = 2 sections each from each mouse. N = 9–10 mice (a vs b, Veh vs Criz, P = 0.0138)

    Springerplus, 2016, 5:348. Crizotinib (PF-02341066) purchased from Selleck.

    Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

    Int J Proteomics 2011 2011, 215496. Crizotinib (PF-02341066) purchased from Selleck.

  • Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. Crizotinib (PF-02341066) purchased from Selleck.

    Western blot analysis of c-Met, MAPK and Akt. 0-100nM PF2341066 was added.

     

     

    Dr. Zhang of Tianjin Medical University. Crizotinib (PF-02341066) purchased from Selleck.

製品安全説明書

c-Met阻害剤の選択性比較

生物活性

製品説明 Crizotinib (PF-02341066)は一種の有効なc-MetとALK阻害剤で、細胞試験でIC50値が11 nMと24 nMです。
ターゲット
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
11 nM 24 nM
体外試験

PF-2341066 displays similar potency against c-Met phosphorylation in mIMCD3 mouse or MDCK canine epithelial cells with IC50 of 5 nM and 20 nM, respectivly. PF-2341066 shows improved or similar activity against NIH3T3 cells engineered to express c-Met ATP-binding site mutants V1092I or H1094R or the P-loop mutant M1250T with IC50 of 19 nM, 2 nM and 15 nM, respectively, compared with NIH3T3 cells expressing wild-type receptor with IC50 of 13 nM. In contrast, a marked shift in potency of PF-2341066 is observed against cells engineered to express c-Met activation loop mutants Y1230C and Y1235D with IC50 of 127 nM and 92 nM, respectively, compared with wild-type receptor. PF-2341066 also potently prevents the phosphorylation of c-Met in NCI-H69 and HOP92 cells, with IC50 of 13 nM and 16 nM, respectively, which express the endogenous c-Met variants R988C and T1010I, respectively. PF-2341066 is >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB, all compared with c-Met. PF-2341066 is 20- to 30-fold selective for RON and Axl RTKs. In contrast, PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion variant of the ALK RTK expressed by the KARPAS299 human anaplastic large cell lymphoma (ALCL) cell line. PF-2341066 inhibits c-Met–dependent neoplastic phenotypes of cancer cells and angiogenic phenotypes of endothelial cells. PF-2341066 suppresses human GTL-16 gastric carcinoma cell growth with IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with IC50 of 8.4 nM. PF-2341066 inhibits HGF-stimulated human NCI-H441 lung carcinoma cell migration and invasion with IC50 of 11 nM and 6.1 nM, respectively. PF-2341066 inhibits MDCK cell scattering with IC50 of 16 nM. PF-2341066 prevents HGF-stimulated c-Met phosphorylation, cell survival, and Matrigel invasion with IC50 of 11 nM, 14 nM and 35 nM, respectively. In addition, PF-2341066 prevents serum-stimulated HMVEC branching tubulogenesis (formation of vascular tubes) in fibrin gels. [1] PF-2341066 also potently inhibits NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells with an IC50 of 24 nM. PF-2341066 potently prevents cell proliferation, which is associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells with IC50 of 30 nM, but not ALK-negative lymphoma cells. [2] Besides, PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (i.e., proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 NGrLUZZEgXSxdH;4bYMhSXO|YYm= M3TYTlQ5KGh? NUHHVoNxTE2VTx?= MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochSUyNIF[xNVc1VCCvdYThcpQh[2:neIDy[ZN{cW6pIFXNUFQhf2m2aDDJR|UxKG:oIECuOlIh|ryP M4XkTFIyPTd{NUi5
BAF3 Mm[zR5l1d3SxeHnjJGF{e2G7 NVPicml3PDhiaB?= Ml;QSG1UVw>? MX\DfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochSUyNIFyxNVk3VSCvdYThcpQh[2:neIDy[ZN{cW6pIFXNUFQhf2m2aDDJR|UxKG:oIEKuNkDPxE1? MYqyNVU4OjV6OR?=
BAF3 MWPDfZRwfG:6aXOgRZN{[Xl? MkLJOFghcA>? Mnn1SG1UVw>? M2PQTWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCHTVy0MWFNUyC5aYToJGlEPTBib3[gNE4zQCEQvF2= MUmyNVU4OjV6OR?=
Kelly M2jyTmN6fG:2b4jpZ{BCe3OjeR?= MXjEUXNQ NVe3XGR3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU2WubImgZ4VtdHNiZYjwdoV{e2mwZzDBUGshTjFzN{TMJI12fGGwdDD3bZRpKEmFNUCgc4YhOC52MjFOwG0> M37LT|IyPTd{NUi5
SH-SY5Y M{fjRmN6fG:2b4jpZ{BCe3OjeR?= NYH3bJc4TE2VTx?= MWfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTTE1UYTW\IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRid3n0bEBKSzVyIH;mJFAvPTNizszN NWPsUnVQOjF3N{K1PFk>
SMS-KCN NEPiSpREgXSxdH;4bYMhSXO|YYm= NUjPWYZXTE2VTx?= MV3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTUXMuU0OQIHPlcIx{KGW6cILld5NqdmdiQVzLJHIyOjd3UTDteZRidnRid3n0bEBKSzVyIH;mJFAvQTFizszN M1TLZlIyPTd{NUi5
BAF3 NVLybW5sS3m2b4TvfIlkKEG|c3H5 NXPzSYJoPDhiaB?= M3mwNGROW09? NGnO[WlEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSUZ|IHPlcIx{KGW6cILld5NqdmdiVHXsMWFNUyC5aYToJGlEPTBib3[gNE4yQSEQvF2= NIG5XlkzOTV5MkW4PS=>
3T3 MVTGeY5kfGmxbjDBd5NigQ>? NG\wbo8yKGh? M{X4Z2ROW09? NH\DN|RKdmirYnn0bY9vKG:oIGLPUkBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wPEDPxE1? NGi5PY4zOThzMkSxOC=>
3T3-E NVfEcGRZTnWwY4Tpc44hSXO|YYm= NVjVTFhKOSCq NGnLbXpFVVOR Mm\xTY5pcWKrdHnvckBw\iCWSVWyJIF{e2W|c3XkJIdzd3e2aDDmZYN1d3JvaX7keYNm\CCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjR2ODFOwG0> MU[yNVgyOjRzNB?=
A549 MkLTT4lv[XOnIFHzd4F6 MXexJIg> M2fSPGROW09? M3q1ZmlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiYz3NSXQhc2mwYYPlJIV5eHKnc4Pl[EBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGhITi2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODB6IN88US=> MlfQNlE5OTJ2MUS=
BAF3-BCL MkPTSpVv[3Srb36gRZN{[Xl? NVvESlY{OSCq M{HJfGROW09? NUHTOJJrUW6qaXLpeIlwdiCxZjDBRmwh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIEGuNVU6KM7:TR?= NXXS[4xmOjF6MUK0NVQ>
HEK293 M1XUcWZ2dmO2aX;uJGF{e2G7 MV2xJIg> MkTGSG1UVw>? NVHrS41rUW6qaXLpeIlwdiCxZjDBXGwh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNlk1KM7:TR?= NUPI[pJnOjF6MUK0NVQ>
HEK293 M4n2WGZ2dmO2aX;uJGF{e2G7 M4DrOVEhcA>? M2XIPWROW09? M3n5[2lvcGmkaYTpc44hd2ZiSWKgZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDJwOEi3JO69VQ>? MYOyNVgyOjRzNB?=
Jurkat NUXRWVZTTnWwY4Tpc44hSXO|YYm= M2D3cFEhcA>? M4fGfmROW09? MWrJcohq[mm2aX;uJI9nKEyFSzDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOi55NEGg{txO NEHBXGEzOThzMkSxOC=>
KARPAS299 NYPpfXVGU2mwYYPlJGF{e2G7 MUOxJIg> NETJVGVFVVOR MmHMTY5pcWKrdHnvckBw\iCDTFugZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEKg{txO NXPpelBNOjF6MUK0NVQ>
PAE MkGzSpVv[3Srb36gRZN{[Xl? NESxNZoyKGh? MVXEUXNQ NXL3VlR1UW6qaXLpeIlwdiCxZjDUVmtDKGG|c3Xzd4VlKGG|IHfyc5d1cCCoYXP0c5IucW6mdXPl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlM6QSEQvF2= MUeyNVgyOjRzNB?=
BAF3 M4nENmZ2dmO2aX;uJGF{e2G7 NVvVT4pTOi1|IHS= NFfDZZpFVVOR MVjJcohq[mm2aX;uJI9nKFSHTD3meZNm\CCrboP1cIlvKHKnY3XweI9zKGW6cILld5Nm\CC5aYToJGlEPTBib3[gNU43PDNizszN Mm\kNlM4PDJ{NUK=
KARPAS299 NHzySndEgXSxdH;4bYMhSXO|YYm= M4jt[FIuOyCm MmftSG1UVw>? NXTkTmlqUUN3ME2wMlA3PDJizszN MkXHNlM4PDJ{NUK=
EBC1 M3fBNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrPeHVNPzJiaB?= M3PIcGROW09? NXXLOlliUUN3ME2wMlAzOyEQvF2= NH7WZm0zOzl7M{OyPC=>
HCT116 MlPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\H[HY4OiCq NFK1c5ZFVVOR MkDzTWM2OD1zND64NkDPxE1? MVmyN|k6OzN{OB?=
MCF7 M2K0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrhSGU4OiCq NXfvVHpJTE2VTx?= MkjMTWM2OD17LkW4JO69VQ>? NUTu[oVZOjN7OUOzNlg>
MDA-MB-231 M3fEdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3Re5VxPzJiaB?= M4LPd2ROW09? NWTQSZNWUUN3ME2xNE45KM7:TR?= NXGxWGtSOjN7OUOzNlg>
MKN45 NEPC[phIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkToO|IhcA>? MVzEUXNQ MVLJR|UxRTBwMEGzJO69VQ>? NVTQTGVsOjN7OUOzNlg>
NCI-H441 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWW3NkBp MlzmSG1UVw>? NGT3eGlKSzVyPUG3MlI2KM7:TR?= NG\ZS3YzOzl7M{OyPC=>
NCI-H661 NXjQcXlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEC3OWo4OiCq NIrBVFVFVVOR Mn3ETWM2OD1zMT60O{DPxE1? Mn;QNlM6QTN|Mki=
SK-MEL-28 MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPwSXc4OiCq M1HT[mROW09? MV\JR|UxRTFyLkm3JO69VQ>? NEXZZYIzOzl7M{OyPC=>
SKOV3 MnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDUTIw4OiCq NUnzN|NETE2VTx?= NXHyOlU{UUN3ME2xNk45PSEQvF2= NVzRU4wyOjN7OUOzNlg>
SNU5 NXzLeWt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrHe29NPzJiaB?= MVvEUXNQ NXWxbZR1UUN3ME2wMlAyPiEQvF2= Mmi4NlM6QTN|Mki=
NCI-H2228 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7BRnNpPzJiaB?= MmPDSG1UVw>? MVjJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4yOThizszN NUTDUmdsOjR2M{K5NFk>
NCI-H3122 MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[wO|IhcA>? NYXuVnhYTE2VTx?= M{PmZ2lvcGmkaYTpc44hd2ZiQVzLMYZ2e2mxbjDkdol3\W5iY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjFyODFOwG0> M{Hr[VI1PDN{OUC5
NCI-H3122 NV2yVlF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXZ[45[PzJiaB?= MYfEUXNQ NGK4PJFKdmirYnn0bY9vKG:oIFHMT{1nfXOrb36g[JJqfmWwIHPlcIwheHKxbHnm[ZJifGmxbjDpckBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNiaHHyZo9zcW6pIFHMT{BIOTJ4OVGgcZV1[W62IIfpeIghUUN3MDDv[kAxNjZ{MzFOwG0> NWWwNIdyOjR2M{K5NFk>
NCI-H3122 NWDWSmRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4ntTVczKGh? NG[4c3BFVVOR MXXJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMhcGG{Yn;ybY5oKEGOSzDMNVE6Pk1ibYX0ZY51KHerdHigTWM2OCCxZjCwMlg{QCEQvF2= MnHuNlQ1OzJ7MEm=
NIH-3T3 NGTxfXlMcW6jc3WgRZN{[Xl? M2XoTVEhcA>? MlnpSG1UVw>? M4HT[WlvcGmkaYTpc44hd2ZiaIXtZY4hf2muZDD0fZBmKEWPTESt[pV{\WRiQVzLJIV5eHKnc4Pl[EBie3Onc4Pl[EBieyCyaH;zdIhwenmuYYTl[EBCVEtibHX2[Ywhf2m2aDDJR|UxKG:oIECuNFgh|ryP NGX0bHgzPDR|MkmwPS=>
NIH-3T3 M2HFbWtqdmG|ZTDBd5NigQ>? NUXRVmR4OSCq M3WyUWROW09? NUDiOmI{UW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BIOTJ4OVGgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD62NFUh|ryP NXjUNmg6OjR2M{K5NFk>
NIH-3T3 MnW1T4lv[XOnIFHzd4F6 MnvaNUBp NU[xU|ZVTE2VTx?= M1TvdGlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugV|EzOD[\IH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwNkK2JO69VQ>? NUPUWGZEOjR2M{K5NFk>
NIH-3T3 MVfLbY5ie2ViQYPzZZk> NV22TnNKOSCq NYHpN|dITE2VTx?= M3uzUmlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugUFEyQT[PIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwOESzJO69VQ>? M{jCdlI1PDN{OUC5
NIH-3T3 NYHoeod5U2mwYYPlJGF{e2G7 M{fo[|EhcA>? NHPKd4lFVVOR NEnBTYJKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGwyOTV{UjDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iBzLkCyOkDPxE1? M1HmN|I1PDN{OUC5
BAF3 MWPGeY5kfGmxbjDBd5NigQ>? M2r2WVczKGh? NXXSN5V1TE2VTx?= NYDrbIo1UW6qaXLpeIlwdiCxZjDOVG0wSUyNIITyZY5{\mWldHXkJIF{e2W|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEWxJO69VQ>? NX;PcZpxOjR2Nki2N|I>
BAF3 MorKR5l1d3SxeHnjJGF{e2G7 NYrofWpyPzJiaB?= M2nERWROW09? NH3CU49KSzVyPUCuPVgh|ryP MX[yOFQ3QDZ|Mh?=
NIH-3T3 NUj2TI5OU2mwYYPlJGF{e2G7 M4\SR|EhcA>? M334emlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugSlEyPzSOIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwMU[1JO69VQ>? NW[yS4RnOjR6MUmxNVY>
NIH-3T3 NYThR5lPU2mwYYPlJGF{e2G7 MYCxJIg> MVLJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFOxNVU3YSCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjR5ODFOwG0> NYnxT5lpOjR6MUmxNVY>
NIH-3T3 MXrLbY5ie2ViQYPzZZk> NFLOT5YyKGh? NWDXc4pEUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BIOTJyMmKgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMT6xOFgh|ryP Mnu3NlQ5OTlzMU[=
NIH-3T3 NXnKeVNDU2mwYYPlJGF{e2G7 M3LlSFEhcA>? M{j1emlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugNVE2OVSrboOgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMz6wN|kh|ryP MVWyOFgyQTFzNh?=
KARPAS299 NV36S2xyU2mwYYPlJGF{e2G7 NUjBZlBCQTBibXnu NWDjcY5STE2VTx?= NV7jOmJjUW6qaXLpeIlwdiCxZjDOVG0u\nW|ZXSgRWxMKHCqb4PwbI9zgWyjdHnvckBmgHC{ZYPz[YQhf2m2aDDJR|UxKG:oIECuNVEh|ryP M3vrfFI1QTByN{Ww
MKN 45 M3vTUmtqdmG|ZTDBd5NigQ>? NEjTUmEyKGh? NWjXOpZFTE2VTx?= MXzJcohq[mm2aX;uJI9nKGNvTXX0JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMjFOwG0> NHTJRWczPDlyMEe1NC=>
A549 MVfDfZRwfG:6aXOgRZN{[Xl? MorJOFghcA>? MlP1SG1UVw>? M{TRTmlEPTBib3[gOE4xQDRizszN MlrwNlQ6ODB6M{C=
NCI-H1975 MnPqR5l1d3SxeHnjJGF{e2G7 MYi0PEBp Mmr4SG1UVw>? MXHJR|UxKG:oIEeuOVUyKM7:TR?= M1fPNlI1QTByOEOw
NCI-H1993 MX3DfZRwfG:6aXOgRZN{[Xl? NGjnVGU1QCCq MlPRSG1UVw>? MWjJR|UxKG:oIECuNFYyKM7:TR?= NX7ze3BGOjR7MEC4N|A>
NCI-H1993 NXGwbWF6SXCxdH;zbZMhSXO|YYm= NXHW[ZZmOSEQvF2= NGjEUXgzPCCq M4TwcGROW09? NELYW4Jld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nz NUL1WWRJOjR7MEC4N|A>
NIH-3T3 MoXXR5l1d3SxeHnjJGF{e2G7 MkTYOFghcA>? NGq0VItFVVOR NHTpcYdKSzVyIH;mJFAvOzZ2IN88US=> Mly0NlQ6ODB6M{C=
EBC1 MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr2XHhlPzJiaB?= M4q5bWROW09? M4S0V2lEPTBib3[gNE4xODZ7IN88US=> M33KOVI1QTByOEOx
KARPAS299 M1XuXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\K[2U4OiCq NF;FNo9FVVOR NGr6XJdKSzVyIH;mJFAvOiEQvF2= M37rPFI1QTByOEOx
NB1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYn1[3g4UUN3ME25NU46QCCwTR?= NYfWVnpyW0GQR1XS
NCI-SNU-5 M4qyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zIbGlEPTB;MUC1Mlc2KG6P M2nEWXNCVkeHUh?=
SR NEjTemNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPnb5dDUUN3ME2xNlYvOzFibl2= MmGzV2FPT0WU
SF539 M2DNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzKTWM2OD1{MESuNlQhdk1? MYTTRW5ITVJ?
SU-DHL-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTWO2hOUUN3ME2zN|YvQDJibl2= MmXVV2FPT0WU
SCC-3 NVvXWHBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTN3Nj63OkBvVQ>? NWDmPXRyW0GQR1XS
DEL NVq2[3VCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{j5dWlEPTB;M{[5Mlkhdk1? NHzDT5ZUSU6JRWK=
CTV-1 MlzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTV7Nj60PEBvVQ>? MUPTRW5ITVJ?
EM-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTZyMT6zOEBvVQ>? M2jUW3NCVkeHUh?=
MHH-CALL-2 M2f1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjVN|BKSzVyPU[4Nk42PyCwTR?= NVjvPZM{W0GQR1XS
KM12 NXjubllPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfoUVlKSzVyPUewOk46KG6P MlHpV2FPT0WU
KINGS-1 M1LqVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TiOGlEPTB;N{S5Mlc2KG6P M1jtSXNCVkeHUh?=
MEG-01 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17MUmlEPTB;OEW3MlY3KG6P NGq5[mxUSU6JRWK=
BV-173 NXLJSGpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPtXFZKSzVyPUGuNFU6QTdizszN M2jxb3NCVkeHUh?=
LAMA-84 NHPwcY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTFwM{iyPFIh|ryP MnjVV2FPT0WU
KARPAS-299 MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvYT4pSUUN3ME2xMlQxQDZzIN88US=> Ml;vV2FPT0WU
K-562 NVnZRmt4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLwS2tKSzVyPUGuO|IzPjlizszN M1HTPHNCVkeHUh?=
SK-LMS-1 MnfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknpTWM2OD1zLke2PFY4KM7:TR?= NUS5bIhXW0GQR1XS
MOLT-16 Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTFwOUW1O|Uh|ryP MXrTRW5ITVJ?
CMK NILPNXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Cw[GlEPTB;MT65OlE2QSEQvF2= NXrOOZBVW0GQR1XS
ST486 NHrxXGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LCNWlEPTB;Mj60N|A4OyEQvF2= NYnxfFI5W0GQR1XS
CI-1 NXXkblU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTwU3dKSzVyPUKuOFk3PTlizszN NXzhdWpXW0GQR1XS
KP-N-RT-BM-1 M2W5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHzb4hDUUN3ME2yMlcxOTJ{IN88US=> M1;ZVnNCVkeHUh?=
ALL-PO MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7lfVFKSzVyPUOuNVgzODdizszN NULJWJZ4W0GQR1XS
KS-1 NIrsWVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVu3bXU4UUN3ME2zMlIyOjJ3IN88US=> MYnTRW5ITVJ?
Becker MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmS4TWM2OD12LkKzPVMh|ryP MYrTRW5ITVJ?
GDM-1 M1naSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvrWlNpUUN3ME20MlI1PjF5IN88US=> MlrNV2FPT0WU
BC-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTRwNEmyO|ch|ryP MnvCV2FPT0WU
NB14 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXOe21vUUN3ME20Mlg{PTJ2IN88US=> NYHP[5YzW0GQR1XS
NOS-1 M4DCW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVz2d2xwUUN3ME21MlM{QDd2IN88US=> NWP0XIlEW0GQR1XS
MZ1-PC NYLwOppGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTVwOEKxOVEh|ryP MY\TRW5ITVJ?
A498 NEO4WXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDxTWM2OD14LkC4OFc{KM7:TR?= M4TXZ3NCVkeHUh?=
EW-16 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTZwM{e3O|Mh|ryP MVnTRW5ITVJ?
NALM-6 NX\qdZIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\nTWM2OD14Lk[4N|g4KM7:TR?= NVfuTmdYW0GQR1XS
EB-3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn63TWM2OD15LkC3NlM{KM7:TR?= MlT2V2FPT0WU
697 NHXiN3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTlwMkSzNlkh|ryP Mn3wV2FPT0WU
Ramos-2G6-4C10 MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTlwNUm4OFIh|ryP MXTTRW5ITVJ?
KNS-81-FD NX\sRpl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\XeoxbUUN3ME25MlY6PjV|IN88US=> MkPpV2FPT0WU
HUTU-80 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXTTWM2OD17Lke0OlQzKM7:TR?= M3LYOXNCVkeHUh?=
LS-411N M2Dmd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\zTWM2OD1zMD6wOVY4KM7:TR?= NGfhXWVUSU6JRWK=
RPMI-8402 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LHfmlEPTB;MUCuNVE3KM7:TR?= MmXMV2FPT0WU
KU812 M4TSTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LtVmlEPTB;MUCuNlk6OSEQvF2= M1jUN3NCVkeHUh?=
EW-1 NEPvNWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTFyLkS0NlUh|ryP MYHTRW5ITVJ?
HC-1 NWO2ZpVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTFyLkS4OFQh|ryP MUXTRW5ITVJ?
NB69 MofLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInvVnVKSzVyPUGwMlUxPDNizszN Mn:3V2FPT0WU
MFH-ino MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:0dWFKSzVyPUGwMlg{ODNizszN NWW5V|JJW0GQR1XS
CCRF-CEM MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jSU2lEPTB;MUGuOVk4KM7:TR?= NWPBU3NxW0GQR1XS
SK-N-DZ MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1u1O2lEPTB;MUKuNFQ{PiEQvF2= MYHTRW5ITVJ?
NCI-H720 M4jxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITqXG9KSzVyPUGyMlE4ODVizszN MYrTRW5ITVJ?
HCC1187 NETnT3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGH4dXFKSzVyPUGyMlIxPDFizszN MmnkV2FPT0WU
IST-SL2 Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\2VnYzUUN3ME2xNk41QDd{IN88US=> NVLVOlBFW0GQR1XS
KE-37 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33vUGlEPTB;MUKuO|k3PiEQvF2= NH\VfZFUSU6JRWK=
HCC1599 NF;aSHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTF{LkmwOlkh|ryP NHjvcIhUSU6JRWK=
A4-Fuk NHrYUVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFyxeWFKSzVyPUGyMlk2QDZizszN MnrDV2FPT0WU
NKM-1 M{D6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWe0S2tRUUN3ME2xN{4zQTJ3IN88US=> MWjTRW5ITVJ?
BE-13 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTF|Lke5PFkh|ryP Mn32V2FPT0WU
MV-4-11 NUf0WWdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPwTWM2OD1zND6wN|I1KM7:TR?= MUHTRW5ITVJ?
OPM-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[wTWM2OD1zND60NFg2KM7:TR?= MWHTRW5ITVJ?
KARPAS-422 M2S4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLHTWM2OD1zND61NVI3KM7:TR?= NGjaV4tUSU6JRWK=
RPMI-8226 M2WzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknPTWM2OD1zND64PVE2KM7:TR?= MUPTRW5ITVJ?
KARPAS-45 NIPzRWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml60TWM2OD1zNT63O|E3KM7:TR?= M4DhfnNCVkeHUh?=
SK-PN-DW NIn1dGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTF3Lki2N|Eh|ryP MonFV2FPT0WU
LC-2 M3;NPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXyTWM2OD1zNj6xOVA3KM7:TR?= M{XMWnNCVkeHUh?=
NCI-H1648 NE\sO5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jXZWlEPTB;MU[uNlU1KM7:TR?= M4DDUXNCVkeHUh?=
RL95-2 Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moq3TWM2OD1zNj6zPVc5KM7:TR?= Mn[2V2FPT0WU
KNS-42 MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jo[2lEPTB;MU[uO|I4PCEQvF2= M4m3XnNCVkeHUh?=
RPMI-6666 NGHzUI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{L6[mlEPTB;MU[uPVIyOSEQvF2= NVPsb4NxW0GQR1XS
SIG-M5 MoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTF5LkG5NFMh|ryP NGDTN4lUSU6JRWK=
VA-ES-BJ NGrUU5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1OxPWlEPTB;MUeuO|Q2OSEQvF2= MWnTRW5ITVJ?
MONO-MAC-6 NWHrOmlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\IfGlEPTB;MUeuPVMyOiEQvF2= MVjTRW5ITVJ?
LAN-6 NWrrcpZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHwTWM2OD1zOD63OVU4KM7:TR?= MYPTRW5ITVJ?
A388 NXHrdGJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1O4OmlEPTB;MUmuN|A2QSEQvF2= Mm\lV2FPT0WU
SK-NEP-1 NUPKXpY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTJyLkKxN|Ih|ryP MUnTRW5ITVJ?
TE-10 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrZXG9[UUN3ME2yNE42OjJzIN88US=> MYfTRW5ITVJ?
HL-60 MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmK2TWM2OD1{MD65NFk6KM7:TR?= NIPseXVUSU6JRWK=
MC116 Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJzLkeyNlEh|ryP NVPxd5dbW0GQR1XS
SW962 NE\xOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHQTWM2OD1{MT63PVE2KM7:TR?= NYrve2hUW0GQR1XS
NOMO-1 MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTJ{Lk[1OlQh|ryP MofNV2FPT0WU
CTB-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDQTWM2OD1{Mj64OlcyKM7:TR?= MnraV2FPT0WU
MRK-nu-1 NUS0[HR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjrR4dKSzVyPUKyMlkxPzRizszN Mn;2V2FPT0WU
GR-ST NH\k[3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jSUGlEPTB;MkOuO|Yh|ryP NV;ZZYgzW0GQR1XS
HH M3f5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJ2LkCwN{DPxE1? MoPVV2FPT0WU
NCI-H1963 MnrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof1TWM2OD1{ND6wO|gzKM7:TR?= M{C2WXNCVkeHUh?=
QIMR-WIL MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlT1TWM2OD1{ND64O|czKM7:TR?= MlzYV2FPT0WU
CGTH-W-1 NV\tSFhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTJ3LkC3NlMh|ryP NGjhRmtUSU6JRWK=
LP-1 NVjXe2NqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTJ3Lk[1OVEh|ryP M3nHd3NCVkeHUh?=
NCI-H748 M2LIVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDXWFBKSzVyPUK2MlUyOzdizszN MUfTRW5ITVJ?
PF-382 MmXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XTRWlEPTB;MkeuNlIzOyEQvF2= Moe5V2FPT0WU
ATN-1 NUfhcotGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVW4SlhyUUN3ME2yO{4{PzN{IN88US=> M3LuUXNCVkeHUh?=
L-540 MmXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXWTWM2OD1{Nz62OFU6KM7:TR?= M4e4U3NCVkeHUh?=
LXF-289 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTaWItKSzVyPUK3Mlc2OTlizszN NGDUfWlUSU6JRWK=
LS-513 NIPkb5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHGTWM2OD1{OD6xPFA4KM7:TR?= MojwV2FPT0WU
NCI-H1581 NVvLZmVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\vTWM2OD1|MD6zPVc3KM7:TR?= MYHTRW5ITVJ?
ES6 M3z5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTpTWM2OD1|MD62PFk6KM7:TR?= Mk\iV2FPT0WU
SW982 M{DMUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvjTWM2OD1|MD64OVY3KM7:TR?= Ml;EV2FPT0WU
DOHH-2 NFv2dpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\vcmlEPTB;M{GuOVg6OyEQvF2= NUDtd45[W0GQR1XS
DB M2\pdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTN|Lkm0N|Eh|ryP M3rVeHNCVkeHUh?=
MPP-89 NFvJUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLOOZBbUUN3ME2zOE4yPzV4IN88US=> NX[0NZZmW0GQR1XS
LB831-BLC MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfR[2JKSzVyPUO0MlUyQDRizszN NEnUW5FUSU6JRWK=
NB5 NYT6WJhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTOTWM2OD1|ND64OVM2KM7:TR?= MXrTRW5ITVJ?
GB-1 NFvOe41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;mOFg6UUN3ME2zOU4xPDZ7IN88US=> MVTTRW5ITVJ?
TE-15 M2K1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7IVIhKSzVyPUO1MlIzOzhizszN MXTTRW5ITVJ?
LC4-1 NHXCS3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHyzO|ZKSzVyPUO1MlM5PDdizszN MonmV2FPT0WU
NCI-H747 Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTN4LkGzOlkh|ryP NVSyOXpXW0GQR1XS
NTERA-S-cl-D1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV[2UnJTUUN3ME2zPE44OzR5IN88US=> MonoV2FPT0WU
SK-MM-2 M4j4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTRyLkGxOFYh|ryP MlOxV2FPT0WU
TGW NF;IXoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTRzLkC1OlMh|ryP M4n5XnNCVkeHUh?=
ONS-76 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7ITWM2OD12Mj60PFg{KM7:TR?= M4T2dXNCVkeHUh?=
CPC-N MlnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYS2eVA6UUN3ME20Nk46QTdzIN88US=> MWDTRW5ITVJ?
ES4 M3vWUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHZPYdsUUN3ME20OE41OTV|IN88US=> M4SzVHNCVkeHUh?=
Daudi M{jJVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PLc2lEPTB;NEWuNFgzPyEQvF2= NHHiXWhUSU6JRWK=
MOLT-4 M13Cbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\iTWM2OD12NT6wPFU{KM7:TR?= MkGyV2FPT0WU
HT-144 MmrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTR4LkeyOkDPxE1? M4DXWXNCVkeHUh?=
SW872 NH\4N4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrneFBYUUN3ME20PE4yQTN|IN88US=> NIj5U4lUSU6JRWK=
D-283MED NHn2Nm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLFNI5KSzVyPUS4MlM2PDJizszN NIHO[Y5USU6JRWK=
NCI-H2126 NXfnfJhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTR6Lki0O|Yh|ryP MnvEV2FPT0WU
NCI-SNU-16 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq1Z49SUUN3ME20PU4zOTR|IN88US=> MmXrV2FPT0WU
CESS MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTR7LkWwPFgh|ryP MUTTRW5ITVJ?
A101D NF\ieGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrmVJdFUUN3ME20PU46PzN4IN88US=> MWDTRW5ITVJ?

多くの細胞株試験データを見る場合、クリックしてください

体内試験 In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm3) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066.[1] P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts leads to dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. In addition, inhibition of key NPM-ALK signaling mediators, including phospholipase C-gamma, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 are observed at concentrations or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.[2] PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts are prevented by PF-2341066.[3] Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in 18F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1.[4]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Cellular kinase phosphorylation ELISA assays:

Cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
細胞試験:

[1]

+ 展開
  • 細胞株: GTL-16 gastric carcinoma cells and T47D breast carcinoma cells
  • 濃度: 0-256 nM
  • 反応時間: 1 hour
  • 実験の流れ:

    Cells including GTL-16 gastric carcinoma cells and T47D breast carcinoma cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 hours. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 minutes. After incubation of cells with PF-2341066 for 1 hour and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4 °C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3,5,5-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Female or male nu/nu mice bearing NCI-H441,or DLD-1, or MDA-MB-231
  • 製剤: --
  • 投薬量: 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day
  • 投与方法: Administered via p.o.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 9 mg/mL (19.98 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
5% DMSO+30% PEG 300+dd H2O
5mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 450.34
化学式

C21H22Cl2FN5O

CAS No. 877399-52-5
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03052608 Not yet recruiting Carcinoma, Non-Small-Cell Lung Pfizer March 2017 Phase 3
NCT02838420 Recruiting Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer Hoffmann-La Roche August 2016 Phase 3
NCT02836847 Recruiting Cholangiocarcinoma of the Extrahepatic Bile Duct|Gallbladder Cancer Shanghai Jiao Tong University School of Medicine|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Ruijin Hospital|RenJi Hospital|Eastern Hepatobiliary Surgery Hospital|Huashan Hospital July 2016 Phase 2
NCT02946359 Recruiting Lung Adenocarcinoma Metastatic Chinese PLA General Hospital July 2016 Phase 2
NCT02679170 Recruiting Non-Small Cell Lung Cancer Pfizer June 2016 --
NCT02767804 Recruiting Non-small Cell Lung Cancer Xcovery Holding Company, LLC June 2016 Phase 3

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

  • 回答:

    Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

Related Antibodies

c-Met信号経路図

c-Met Inhibitors with Unique Features

相関c-Met製品

Tags: Crizotinib (PF-02341066)を買う | Crizotinib (PF-02341066) ic50 | Crizotinib (PF-02341066)供給者 | Crizotinib (PF-02341066)を購入する | Crizotinib (PF-02341066)費用 | Crizotinib (PF-02341066)生産者 | オーダーCrizotinib (PF-02341066) | Crizotinib (PF-02341066)化学構造 | Crizotinib (PF-02341066)分子量 | Crizotinib (PF-02341066)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID